Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
In order to obtain genetic information for analysis and their applications for developing new drugs, precise and qualitative nucleic acid extraction steps are essential. This is Viogene’s primary focus. Viogene provides innovative and cutting-edge nucleic acids extraction technologies and products to allow scientists achieve their goals. Viogene currently has more than 40 nucleic acids extraction products for extracting nucleic acids from various biological sources such as animals, plants, microorganisms. Viogene sells its products in more than 30 countries worldwide.
Another part of Viogene’s research and development program is a platform of G protein coupled receptors (GPCRs) related drugs screening from traditional Chinese medicines (TCMs), GPCRs have proved to be very successful drug targets for more than 30% of marketed drugs which target directly or indirectly on GPCRs, which including the top 100 brand name prescription drugs, however mitigating side effects and increasing potency of GPCRs related drugs are marketed needed, Viogene’s GPCRs new drug screening and discovering programs from TCMs offer new solutions and opportunities for achieving the goals.
No.276, Ta-Tung Rd., Sec.1, Shijr,
New Taipei City, Taiwan
PHONE: 886 2 26472259
FAX: 886 2 26475094
Website: www.viogene.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Taiwan’s current health minister reflects on Taiwan’s prestigious healthcare system, the problems in the first generation health insurance system that were fixed in the second, and strategies to rectify the…
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
The Vice President of Merits Health Products discusses the company’s main opportunities and challenges of the past 25 years, which countries are among its top buyers and its future plans…
The Deputy Executive Secretary of Taiwan’s National Development Fund discusses the recent shift in focus from semiconductors to biotech investments; why this has been a huge success thus far and…
YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill…
Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and…
Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded…
Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp.…
Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API…
PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
See our Cookie Privacy Policy Here
